Dresser, George K.

Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition

Dresser, G. K., Spence, J. D., & Bailey, D. G. (2000) · Clinical Pharmacokinetics

Pharmacogenetics and Drug MetabolismDrug Transport and Resistance Mechanisms

Cited by 908

Hypertension Canada’s 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children

Rabi, D. M., McBrien, K. A., Sapir-Pichhadze, R., Nakhla, M., Ahmed, S. B., Dumanski, S. M., Butalia, S., Leung, A. A., Harris, K. C., Cloutier, L., et al. (2020) · Canadian Journal of Cardiology

Blood Pressure and Hypertension StudiesClinical practice guidelines implementation

Cited by 583

Hypertension Canada’s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children

Nerenberg, K. A., Zarnke, K. B., Leung, A. A., Dasgupta, K., Butalia, S., McBrien, K., Harris, K. C., Nakhla, M., Cloutier, L., Gelfer, M., et al. (2018) · Canadian Journal of Cardiology

Blood Pressure and Hypertension StudiesClinical practice guidelines implementation

Cited by 573

Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care

DeGorter, M. K., Tirona, R. G., Schwarz, U. I., Choi, Y.-H., Dresser, G. K., Suskin, N., Myers, K., Zou, G., Iwuchukwu, O., Wei, W.-Q., et al. (2013) · Circulation: Cardiovascular Genetics

Pharmacogenetics and Drug MetabolismLipoproteins and Cardiovascular Health

Cited by 195